GlaxoSmithKline plc (ADR) (GSK), Theravance Inc (THRX), Pfizer Inc. (PFE): 3 Potential Game Changers for COPD

Page 2 of 2

More to come

These are just three of the most promising COPD drugs on the horizon. The Pharmaceutical Research and Manufacturers of America group reports that there are more than 50 drugs in clinical development or awaiting regulatory approval that target treatment of COPD. These advancements hold the potential to help COPD patients, as well as deliver profits to the investors in those companies that lead the way.

The article 3 Potential Game Changers for COPD originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2